All AbMole products are for research use only, cannot be used for human consumption.
SB-525334 is a potent and selective inhibitor of the transforming growth factor-beta1 (TGF-beta1) receptor, activin receptor-like kinase (ALK5). In cell-based assays, SB-525334 (1 microM) blocked TGF-beta1-induced phosphorylation and nuclear translocation of Smad2/3 in renal proximal tubule cells and inhibited TGF-beta1-induced increases in plasminogen activator inhibitor-1 (PAI-1) and procollagen alpha1(I) mRNA expression in A498 renal epithelial carcinoma cells. SB-525334 inhibited ALK5 kinase activity with an IC50 of 14.3 nM and was approximately 4-fold less potent as an inhibitor of ALK4 with IC50 of 58.5 nM. SB-525334 significantly increased apoptotic cell death in gemcitabine-resistant cells. SB-525334 reverses pulmonary arterial pressure and inhibits right ventricular hypertrophy in a rat model of PAH effectively. SB-525334 treatment showed significant attenuation in Smad2/3 nuclear translocation, decrease in CTGF-expressing cells, myofibroblast proliferation and type I collagen deposition.
Cancer Biother Radiopharm. 2020 Mar;35(2):120-128.
Activation of TGF-β1 Pathway by SCUBE3 Regulates TWIST1 Expression and Promotes Breast Cancer Progression.
SB-525334 purchased from AbMole
J Cell Physiol. 2019 Jun;234(6):9698-9710.
H19/miR-148a/USP4 axis facilitates liver fibrosis by enhancing TGF-β signaling in both hepatic stellate cells and hepatocytes.
SB-525334 purchased from AbMole
Oncol Lett. 2018 Dec 10.
Pancreatic stellate cells facilitate pancreatic cancer cell viability and invasion.
SB-525334 purchased from AbMole
 |
Source | Am J Physiol Renal Physiol (2015). Figure 4. SB-525334 |
| Method | Endothelial function | |
| Cell Lines | rats | |
| Concentrations | - | |
| Incubation Time | 24-h | |
| Results | Aortic endothelial cell lysates obtained from the four groups of rats on day 7 of the experiment demonstrated activation of ALK5 by HS intake as well as the anticipated inhibition of ALK5 by SB-525334 |
| Molecular Weight | 343.42 |
| Formula | C21H21N5 |
| CAS Number | 356559-20-1 |
| Solubility (25°C) | DMSO 60 mg/mL Ethanol 40 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related TGF-β Receptor Products |
|---|
| CJJ300
CJJ300 is a transforming growth factor-β (TGF-β) inhibitor with an IC50 of 5.3 µM. |
| AZ12601011
AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor with an IC50 of 18 nM and a Kd of 2.9 nM. AZ12601011 inhibits phosphorylation of SMAD2 via selectively inhibiting ALK4, TGFBR1, and ALK7. AZ12601011 inhibits mammary tumor growth. |
| TGF-βRI inhibitor 1
TGF-βRI inhibitor 1 (compoimd i) is a TGF-βRI inhibitor. |
| TGF-βRI inhibitor 1 methylbenzenesulfonate
TGF-βRI inhibitor 1 (compoimd i) methylbenzenesulfonate is a TGF-βRI inhibitor. |
| LSKL TFA
LSKL TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
